Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome.

Passet M, Boissel N, Sigaux F, Saillard C, Bargetzi M, Ba I, Thomas X, Graux C, Chalandon Y, Leguay T, Lengliné E, Konopacki J, Quentin S, Delabesse E, Lafage-Pochitaloff M, Pastoret C, Grardel N, Asnafi V, Lhéritier V, Soulier J, Dombret H, Clappier E; Group for Research on Adult ALL (GRAALL).

Blood. 2019 Jan 17;133(3):280-284. doi: 10.1182/blood-2018-10-882142. Epub 2018 Dec 3. No abstract available.

PMID:
30510083
2.

The impact of chronic myeloid leukemia on employment: the French prospective study.

De Barros S, Vayr F, Despas F, Strumia M, Podevin C, Gauthier M, Delabesse E, Soulat JM, Laurent G, Huguet F, Herin F.

Ann Hematol. 2019 Mar;98(3):615-623. doi: 10.1007/s00277-018-3549-5. Epub 2018 Nov 17.

PMID:
30446803
3.

Hydroxyurea prior to intensive chemotherapy in AML with moderate leukocytosis.

Bertoli S, Tavitian S, Picard M, Huguet F, Vergez F, Delabesse E, Sarry A, Bérard E, Récher C.

Leuk Res. 2018 Dec;75:7-10. doi: 10.1016/j.leukres.2018.10.015. Epub 2018 Oct 31. No abstract available.

PMID:
30419550
4.

Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia.

Bertoli S, Paubelle E, Bérard E, Saland E, Thomas X, Tavitian S, Larcher MV, Vergez F, Delabesse E, Sarry A, Huguet F, Larrue C, Bosc C, Farge T, Sarry JE, Michallet M, Récher C.

Eur J Haematol. 2019 Feb;102(2):131-142. doi: 10.1111/ejh.13183. Epub 2018 Nov 28.

PMID:
30325535
5.

Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial.

Pigneux A, Béné MC, Salmi LR, Dumas PY, Delaunay J, Bonmati C, Guièze R, Luquet I, Cornillet-Lefebvre P, Delabesse E, Ianotto JC, Ojeda-Uribe M, Hunault M, Banos A, Fornecker LM, Bernard M, Jourdan E, Vey N, Zerazhi H, Hishri Y, Mineur A, Asselineau J, Delepine R, Cahn JY, Ifrah N, Récher C; French Innovative Leukemia Organization.

J Clin Oncol. 2018 Sep 27:JCO2018787366. doi: 10.1200/JCO.2018.78.7366. [Epub ahead of print]

PMID:
30260758
6.

PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice.

Jamrog L, Chemin G, Fregona V, Coster L, Pasquet M, Oudinet C, Rouquié N, Prade N, Lagarde S, Cresson C, Hébrard S, Nguyen Huu NS, Bousquet M, Quelen C, Brousset P, Mancini SJC, Delabesse E, Khamlichi AA, Gerby B, Broccardo C.

Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):10357-10362. doi: 10.1073/pnas.1721678115. Epub 2018 Sep 26.

PMID:
30257940
7.

PAX5A and PAX5B isoforms are both efficient to drive B cell differentiation.

Cresson C, Péron S, Jamrog L, Rouquié N, Prade N, Dubois M, Hébrard S, Lagarde S, Gerby B, Mancini SJC, Cogné M, Delabesse E, Delpy L, Broccardo C.

Oncotarget. 2018 Aug 28;9(67):32841-32854. doi: 10.18632/oncotarget.26003. eCollection 2018 Aug 28.

8.

Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial.

Huguet F, Chevret S, Leguay T, Thomas X, Boissel N, Escoffre-Barbe M, Chevallier P, Hunault M, Vey N, Bonmati C, Lepretre S, Marolleau JP, Pabst T, Rousselot P, Buzyn A, Cahn JY, Lhéritier V, Béné MC, Asnafi V, Delabesse E, Macintyre E, Chalandon Y, Ifrah N, Dombret H; Group of Research on Adult ALL (GRAALL).

J Clin Oncol. 2018 Aug 20;36(24):2514-2523. doi: 10.1200/JCO.2017.76.8192. Epub 2018 Jun 4.

PMID:
29863974
9.

Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia.

Renneville A, Attias P, Thomas X, Bally C, Hayette S, Farhat H, Eclache V, Marceau-Renaut A, Cassinat B, Feuillard J, Terré C, Delabesse E, Park S, Lejeune J, Chevret S, Adès L, Preudhomme C, Fenaux P.

Leukemia. 2018 Sep;32(9):2066-2069. doi: 10.1038/s41375-018-0137-6. Epub 2018 Apr 18. No abstract available.

PMID:
29740159
10.

Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.

Donadieu J, Lamant M, Fieschi C, de Fontbrune FS, Caye A, Ouachee M, Beaupain B, Bustamante J, Poirel HA, Isidor B, Van Den Neste E, Neel A, Nimubona S, Toutain F, Barlogis V, Schleinitz N, Leblanc T, Rohrlich P, Suarez F, Ranta D, Chahla WA, Bruno B, Terriou L, Francois S, Lioure B, Ahle G, Bachelerie F, Preudhomme C, Delabesse E, Cave H, Bellanné-Chantelot C, Pasquet M; French GATA2 study group.

Haematologica. 2018 Aug;103(8):1278-1287. doi: 10.3324/haematol.2017.181909. Epub 2018 May 3.

11.

Dexamethasone in hyperleukocytic acute myeloid leukemia.

Bertoli S, Picard M, Bérard E, Griessinger E, Larrue C, Mouchel PL, Vergez F, Tavitian S, Yon E, Ruiz J, Delabesse E, Luquet I, Linares LK, Saland E, Carroll M, Danet-Desnoyers G, Sarry A, Huguet F, Sarry JE, Récher C.

Haematologica. 2018 Jun;103(6):988-998. doi: 10.3324/haematol.2017.184267. Epub 2018 Mar 8.

12.

A case of B-cell precursor acute lymphoblastic leukemia with IL3-IGH rearrangement revealed by thromboembolism and marked eosinophilia.

Derrieux C, Freynet N, Frayfer J, Delabesse E, Clappier E, Defasque S, Broutier H, Fouillard L.

Leuk Lymphoma. 2018 Oct;59(10):2489-2492. doi: 10.1080/10428194.2018.1430796. Epub 2018 Feb 9. No abstract available.

PMID:
29424254
13.

Bone marrow sites differently imprint dormancy and chemoresistance to T-cell acute lymphoblastic leukemia.

Cahu X, Calvo J, Poglio S, Prade N, Colsch B, Arcangeli ML, Leblanc T, Petit A, Baleydier F, Baruchel A, Landman-Parker J, Junot C, Larghero J, Ballerini P, Delabesse E, Uzan B, Pflumio F.

Blood Adv. 2017 Sep 8;1(20):1760-1772. doi: 10.1182/bloodadvances.2017004960. eCollection 2017 Sep 12.

14.

Improved outcome for AML patients over the years 2000-2014.

Bertoli S, Tavitian S, Huynh A, Borel C, Guenounou S, Luquet I, Delabesse E, Sarry A, Laurent G, Attal M, Huguet F, Bérard E, Récher C.

Blood Cancer J. 2017 Nov 29;7(12):635. doi: 10.1038/s41408-017-0011-1.

15.

Platelet transfusion refractoriness in patients with acute myeloid leukemia treated by intensive chemotherapy.

Comont T, Tavitian S, Bardiaux L, Fort M, Debiol B, Morère D, Bérard E, Delabesse E, Luquet I, Martinez S, Huguet F, Récher C, Bertoli S.

Leuk Res. 2017 Oct;61:62-67. doi: 10.1016/j.leukres.2017.08.015. Epub 2017 Aug 30.

PMID:
28910610
16.

Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia.

Lafage-Pochitaloff M, Baranger L, Hunault M, Cuccuini W, Lefebvre C, Bidet A, Tigaud I, Eclache V, Delabesse E, Bilhou-Nabéra C, Terré C, Chapiro E, Gachard N, Mozziconacci MJ, Ameye G, Porter S, Grardel N, Béné MC, Chalandon Y, Graux C, Huguet F, Lhéritier V, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL).

Blood. 2017 Oct 19;130(16):1832-1844. doi: 10.1182/blood-2017-05-783852. Epub 2017 Aug 8.

17.

The MLL recombinome of acute leukemias in 2017.

Meyer C, Burmeister T, Gröger D, Tsaur G, Fechina L, Renneville A, Sutton R, Venn NC, Emerenciano M, Pombo-de-Oliveira MS, Barbieri Blunck C, Almeida Lopes B, Zuna J, Trka J, Ballerini P, Lapillonne H, De Braekeleer M, Cazzaniga G, Corral Abascal L, van der Velden VHJ, Delabesse E, Park TS, Oh SH, Silva MLM, Lund-Aho T, Juvonen V, Moore AS, Heidenreich O, Vormoor J, Zerkalenkova E, Olshanskaya Y, Bueno C, Menendez P, Teigler-Schlegel A, Zur Stadt U, Lentes J, Göhring G, Kustanovich A, Aleinikova O, Schäfer BW, Kubetzko S, Madsen HO, Gruhn B, Duarte X, Gameiro P, Lippert E, Bidet A, Cayuela JM, Clappier E, Alonso CN, Zwaan CM, van den Heuvel-Eibrink MM, Izraeli S, Trakhtenbrot L, Archer P, Hancock J, Möricke A, Alten J, Schrappe M, Stanulla M, Strehl S, Attarbaschi A, Dworzak M, Haas OA, Panzer-Grümayer R, Sedék L, Szczepański T, Caye A, Suarez L, Cavé H, Marschalek R.

Leukemia. 2018 Feb;32(2):273-284. doi: 10.1038/leu.2017.213. Epub 2017 Jul 13.

18.

Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients.

De Clara E, Gourvest M, Ma H, Vergez F, Tosolini M, Dejean S, Demur C, Delabesse E, Recher C, Touriol C, Martelli MP, Falini B, Brousset P, Bousquet M.

Haematologica. 2017 Oct;102(10):1718-1726. doi: 10.3324/haematol.2017.171645. Epub 2017 Jul 4.

19.

NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis.

Struski S, Lagarde S, Bories P, Puiseux C, Prade N, Cuccuini W, Pages MP, Bidet A, Gervais C, Lafage-Pochitaloff M, Roche-Lestienne C, Barin C, Penther D, Nadal N, Radford-Weiss I, Collonge-Rame MA, Gaillard B, Mugneret F, Lefebvre C, Bart-Delabesse E, Petit A, Leverger G, Broccardo C, Luquet I, Pasquet M, Delabesse E.

Leukemia. 2017 Mar;31(3):565-572. doi: 10.1038/leu.2016.267. Epub 2016 Oct 3.

PMID:
27694926
20.

Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.

Le Bris Y, Struski S, Guièze R, Rouvellat C, Prade N, Troussard X, Tournilhac O, Béné MC, Delabesse E, Ysebaert L.

Hematol Oncol. 2017 Dec;35(4):664-670. doi: 10.1002/hon.2349. Epub 2016 Sep 28.

PMID:
27678008
21.

Unique long non-coding RNA expression signature in ETV6/RUNX1-driven B-cell precursor acute lymphoblastic leukemia.

Ghazavi F, De Moerloose B, Van Loocke W, Wallaert A, Helsmoortel HH, Ferster A, Bakkus M, Plat G, Delabesse E, Uyttebroeck A, Van Nieuwerburgh F, Deforce D, Van Roy N, Speleman F, Benoit Y, Lammens T, Van Vlierberghe P.

Oncotarget. 2016 Nov 8;7(45):73769-73780. doi: 10.18632/oncotarget.12063.

22.

CHK1 as a therapeutic target to bypass chemoresistance in AML.

David L, Fernandez-Vidal A, Bertoli S, Grgurevic S, Lepage B, Deshaies D, Prade N, Cartel M, Larrue C, Sarry JE, Delabesse E, Cazaux C, Didier C, Récher C, Manenti S, Hoffmann JS.

Sci Signal. 2016 Sep 13;9(445):ra90. doi: 10.1126/scisignal.aac9704.

PMID:
27625304
23.

Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.

Boutzen H, Saland E, Larrue C, de Toni F, Gales L, Castelli FA, Cathebas M, Zaghdoudi S, Stuani L, Kaoma T, Riscal R, Yang G, Hirsch P, David M, De Mas-Mansat V, Delabesse E, Vallar L, Delhommeau F, Jouanin I, Ouerfelli O, Le Cam L, Linares LK, Junot C, Portais JC, Vergez F, Récher C, Sarry JE.

J Exp Med. 2016 Apr 4;213(4):483-97. doi: 10.1084/jem.20150736. Epub 2016 Mar 7.

24.

CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.

Bertoli S, Boutzen H, David L, Larrue C, Vergez F, Fernandez-Vidal A, Yuan L, Hospital MA, Tamburini J, Demur C, Delabesse E, Saland E, Sarry JE, Galcera MO, Mansat-De Mas V, Didier C, Dozier C, Récher C, Manenti S.

Oncotarget. 2015 Nov 10;6(35):38061-78. doi: 10.18632/oncotarget.5706.

25.

Impact of obesity in favorable-risk AML patients receiving intensive chemotherapy.

Tavitian S, Denis A, Vergez F, Berard E, Sarry A, Huynh A, Delabesse E, Luquet I, Huguet F, Récher C, Bertoli S.

Am J Hematol. 2016 Feb;91(2):193-8. doi: 10.1002/ajh.24228. Epub 2015 Nov 26.

26.

Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells.

Larrue C, Saland E, Boutzen H, Vergez F, David M, Joffre C, Hospital MA, Tamburini J, Delabesse E, Manenti S, Sarry JE, Récher C.

Blood. 2016 Feb 18;127(7):882-92. doi: 10.1182/blood-2015-05-646497. Epub 2015 Aug 18.

27.

Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.

Larrue C, Saland E, Vergez F, Serhan N, Delabesse E, Mansat-De Mas V, Hospital MA, Tamburini J, Manenti S, Sarry JE, Récher C.

Mol Cancer Ther. 2015 Oct;14(10):2364-73. doi: 10.1158/1535-7163.MCT-15-0163. Epub 2015 Jul 23.

28.

A novel method for room temperature distribution and conservation of RNA and DNA reference materials for guaranteeing performance of molecular diagnostics in onco-hematology: A GBMHM study.

Cayuela JM, Mauté C, Fabre AL, Nibourel O, Dulucq S, Delabesse E, Villarèse P, Hayette S, Mozziconacci MJ, Macintyre E; GBMHM.

Clin Biochem. 2015 Oct;48(15):982-7. doi: 10.1016/j.clinbiochem.2015.04.004. Epub 2015 Apr 12.

PMID:
25872147
29.

Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.

Devillier R, Mansat-De Mas V, Gelsi-Boyer V, Demur C, Murati A, Corre J, Prebet T, Bertoli S, Brecqueville M, Arnoulet C, Recher C, Vey N, Mozziconacci MJ, Delabesse E, Birnbaum D.

Oncotarget. 2015 Apr 10;6(10):8388-96.

30.

Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial.

Boissel N, Renneville A, Leguay T, Lefebvre PC, Recher C, Lecerf T, Delabesse E, Berthon C, Blanchet O, Prebet T, Pautas C, Chevallier P, Leprêtre S, Girault S, Bonmati C, Guièze R, Himberlin C, Randriamalala E, Preudhomme C, Jourdan E, Dombret H, Ifrah N.

Haematologica. 2015 Jun;100(6):780-5. doi: 10.3324/haematol.2014.114884. Epub 2015 Feb 24.

31.

Comparison of 60 or 90 mg/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics.

Devillier R, Bertoli S, Prébet T, Huguet F, Etienne A, Charbonnier A, Rey J, Delabesse E, D'Incan E, Huynh A, Blaise D, Récher C, Vey N.

Am J Hematol. 2015 Feb;90(2):E29-30. doi: 10.1002/ajh.23884. Epub 2014 Nov 19. No abstract available.

32.

The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia.

Van der Meulen J, Sanghvi V, Mavrakis K, Durinck K, Fang F, Matthijssens F, Rondou P, Rosen M, Pieters T, Vandenberghe P, Delabesse E, Lammens T, De Moerloose B, Menten B, Van Roy N, Verhasselt B, Poppe B, Benoit Y, Taghon T, Melnick AM, Speleman F, Wendel HG, Van Vlierberghe P.

Blood. 2015 Jan 1;125(1):13-21. doi: 10.1182/blood-2014-05-577270. Epub 2014 Oct 15.

33.

Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: an analysis from a regional healthcare network.

Bories P, Bertoli S, Bérard E, Laurent J, Duchayne E, Sarry A, Delabesse E, Beyne-Rauzy O, Huguet F, Récher C.

Am J Hematol. 2014 Dec;89(12):E244-52. doi: 10.1002/ajh.23848. Epub 2014 Oct 20.

34.

Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia.

Prebet T, Bertoli S, Delaunay J, Pigneux A, Delabesse E, Mozziconacci MJ, Bidet A, Recher C, Vey N.

Haematologica. 2014 Oct;99(10):e185-7. doi: 10.3324/haematol.2014.109827. Epub 2014 Jun 27. No abstract available.

35.

Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.

Beldjord K, Chevret S, Asnafi V, Huguet F, Boulland ML, Leguay T, Thomas X, Cayuela JM, Grardel N, Chalandon Y, Boissel N, Schaefer B, Delabesse E, Cavé H, Chevallier P, Buzyn A, Fest T, Reman O, Vernant JP, Lhéritier V, Béné MC, Lafage M, Macintyre E, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL).

Blood. 2014 Jun 12;123(24):3739-49. doi: 10.1182/blood-2014-01-547695. Epub 2014 Apr 16.

36.

Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations.

Guenounou S, Delabesse E, Récher C.

Eur J Haematol. 2014 Dec;93(6):533-6. doi: 10.1111/ejh.12334. Epub 2014 Apr 18.

PMID:
24689895
37.

STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model.

Couronné L, Scourzic L, Pilati C, Della Valle V, Duffourd Y, Solary E, Vainchenker W, Merlio JP, Beylot-Barry M, Damm F, Stern MH, Gaulard P, Lamant L, Delabesse E, Merle-Beral H, Nguyen-Khac F, Fontenay M, Tilly H, Bastard C, Zucman-Rossi J, Bernard OA, Mercher T.

Haematologica. 2013 Nov;98(11):1748-52. doi: 10.3324/haematol.2013.085068. Epub 2013 Jul 19.

38.

Identification of GSX2 and AF10 as NUP98 partner genes in myeloid malignancies.

Soler G, Kaltenbach S, Dobbelstein S, Broccardo C, Radford I, Mozziconacci MJ, Bernard OA, Penard-Lacronique V, Delabesse E, Romana SP.

Blood Cancer J. 2013 Jul 12;3:e124. doi: 10.1038/bcj.2013.20. No abstract available.

39.

The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest.

Ben Abdelali R, Asnafi V, Petit A, Micol JB, Callens C, Villarese P, Delabesse E, Reman O, Lepretre S, Cahn JY, Guillerm G, Berthon C, Gardin C, Corront B, Leguay T, Béné MC, Ifrah N, Leverger G, Dombret H, Macintyre E.

Haematologica. 2013 Nov;98(11):1711-7. doi: 10.3324/haematol.2013.086082. Epub 2013 Jul 5.

40.

Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms.

Pérez C, Pascual M, Martín-Subero JI, Bellosillo B, Segura V, Delabesse E, Álvarez S, Larrayoz MJ, Rifón J, Cigudosa JC, Besses C, Calasanz MJ, Cross NC, Prósper F, Agirre X.

Haematologica. 2013 Sep;98(9):1414-20. doi: 10.3324/haematol.2013.084160. Epub 2013 May 28.

41.

The MLL recombinome of acute leukemias in 2013.

Meyer C, Hofmann J, Burmeister T, Gröger D, Park TS, Emerenciano M, Pombo de Oliveira M, Renneville A, Villarese P, Macintyre E, Cavé H, Clappier E, Mass-Malo K, Zuna J, Trka J, De Braekeleer E, De Braekeleer M, Oh SH, Tsaur G, Fechina L, van der Velden VH, van Dongen JJ, Delabesse E, Binato R, Silva ML, Kustanovich A, Aleinikova O, Harris MH, Lund-Aho T, Juvonen V, Heidenreich O, Vormoor J, Choi WW, Jarosova M, Kolenova A, Bueno C, Menendez P, Wehner S, Eckert C, Talmant P, Tondeur S, Lippert E, Launay E, Henry C, Ballerini P, Lapillone H, Callanan MB, Cayuela JM, Herbaux C, Cazzaniga G, Kakadiya PM, Bohlander S, Ahlmann M, Choi JR, Gameiro P, Lee DS, Krauter J, Cornillet-Lefebvre P, Te Kronnie G, Schäfer BW, Kubetzko S, Alonso CN, zur Stadt U, Sutton R, Venn NC, Izraeli S, Trakhtenbrot L, Madsen HO, Archer P, Hancock J, Cerveira N, Teixeira MR, Lo Nigro L, Möricke A, Stanulla M, Schrappe M, Sedék L, Szczepański T, Zwaan CM, Coenen EA, van den Heuvel-Eibrink MM, Strehl S, Dworzak M, Panzer-Grümayer R, Dingermann T, Klingebiel T, Marschalek R.

Leukemia. 2013 Nov;27(11):2165-76. doi: 10.1038/leu.2013.135. Epub 2013 Apr 30.

42.

SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias.

Damm F, Itzykson R, Kosmider O, Droin N, Renneville A, Chesnais V, Gelsi-Boyer V, de Botton S, Vey N, Preudhomme C, Clavert A, Delabesse E, Park S, Birnbaum D, Fontenay M, Bernard OA, Solary E.

Leukemia. 2013 Jun;27(6):1401-3. doi: 10.1038/leu.2013.35. Epub 2013 Feb 5. No abstract available.

PMID:
23443343
43.

Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia.

Bertoli S, Bérard E, Huguet F, Huynh A, Tavitian S, Vergez F, Dobbelstein S, Dastugue N, Mansat-De Mas V, Delabesse E, Duchayne E, Demur C, Sarry A, Lauwers-Cances V, Laurent G, Attal M, Récher C.

Blood. 2013 Apr 4;121(14):2618-26. doi: 10.1182/blood-2012-09-454553. Epub 2013 Jan 30.

44.

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.

Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P, Blanchet O, Cayuela JM, Recher C, Raffoux E, Delaunay J, Pigneux A, Bulabois CE, Berthon C, Pautas C, Vey N, Lioure B, Thomas X, Luquet I, Terré C, Guardiola P, Béné MC, Preudhomme C, Ifrah N, Dombret H; French AML Intergroup.

Blood. 2013 Mar 21;121(12):2213-23. doi: 10.1182/blood-2012-10-462879. Epub 2013 Jan 15.

45.

High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia.

Pasquet M, Bellanné-Chantelot C, Tavitian S, Prade N, Beaupain B, Larochelle O, Petit A, Rohrlich P, Ferrand C, Van Den Neste E, Poirel HA, Lamy T, Ouachée-Chardin M, Mansat-De Mas V, Corre J, Récher C, Plat G, Bachelerie F, Donadieu J, Delabesse E.

Blood. 2013 Jan 31;121(5):822-9. doi: 10.1182/blood-2012-08-447367. Epub 2012 Dec 6.

46.

Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL.

Garand R, Beldjord K, Cavé H, Fossat C, Arnoux I, Asnafi V, Bertrand Y, Boulland ML, Brouzes C, Clappier E, Delabesse E, Fest T, Garnache-Ottou F, Huguet F, Jacob MC, Kuhlein E, Marty-Grès S, Plesa A, Robillard N, Roussel M, Tkaczuk J, Dombret H, Macintyre E, Ifrah N, Béné MC, Baruchel A.

Leukemia. 2013 Feb;27(2):370-6. doi: 10.1038/leu.2012.234. Epub 2012 Aug 16.

PMID:
23070018
47.

Genetic polymorphisms in ARID5B, CEBPE, IKZF1 and CDKN2A in relation with risk of acute lymphoblastic leukaemia in adults: a Group for Research on Adult Acute Lymphoblastic Leukaemia (GRAALL) study.

Peyrouze P, Guihard S, Grardel N, Berthon C, Pottier N, Pigneux A, Cahn JY, Béné MC, Lhéritier V, Delabesse E, Macintyre E, Thomas X, Dombret H, Ifrah N, Cheok M.

Br J Haematol. 2012 Dec;159(5):599-602. doi: 10.1111/bjh.12063. Epub 2012 Sep 27. No abstract available.

PMID:
23016962
48.

The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors.

Fialin C, Larrue C, Vergez F, Sarry JE, Bertoli S, Mansat-De Mas V, Demur C, Delabesse E, Payrastre B, Manenti S, Roche S, Récher C.

Leukemia. 2013 Feb;27(2):325-35. doi: 10.1038/leu.2012.240. Epub 2012 Aug 20.

PMID:
22902361
49.

PICALM-MLLT10 acute myeloid leukemia: a French cohort of 18 patients.

Borel C, Dastugue N, Cances-Lauwers V, Mozziconacci MJ, Prebet T, Vey N, Pigneux A, Lippert E, Visanica S, Legrand F, Rault JP, Taviaux S, Bastard C, Mugneret F, Collonges Rames MA, Gachard N, Talmant P, Delabesse E, Récher C.

Leuk Res. 2012 Nov;36(11):1365-9. doi: 10.1016/j.leukres.2012.07.008. Epub 2012 Aug 5.

PMID:
22871473
50.

Specific small nucleolar RNA expression profiles in acute leukemia.

Valleron W, Laprevotte E, Gautier EF, Quelen C, Demur C, Delabesse E, Agirre X, Prósper F, Kiss T, Brousset P.

Leukemia. 2012 Sep;26(9):2052-60. doi: 10.1038/leu.2012.111. Epub 2012 Apr 23.

PMID:
22522792

Supplemental Content

Loading ...
Support Center